DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zdq3s7/premature_ovarian) has announced the addition of Global Markets Direct's new report "Premature Ovarian Failure - Pipeline Review, H2 2012" to their offering.
Global Markets Direct's, 'Premature Ovarian Failure - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Premature Ovarian Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ovarian Failure.
Scope
- A snapshot of the global therapeutic scenario for Premature Ovarian Failure.
- A review of the Premature Ovarian Failure products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Premature Ovarian Failure pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- News and deals relating to the products.
Reasons to Buy
- Identify and understand important and diverse types of therapeutics under development for Premature Ovarian Failure.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Premature Ovarian Failure pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
For more information visit http://www.researchandmarkets.com/research/zdq3s7/premature_ovarian
Source: Global Markets Direct